ArticleDrug delivery and translational research2011
Prevention of
Article in Drug delivery and translational research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks.Pharmaceutics · 2025Article
- Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre.The American journal of pathology · 2021Article
- Recent Advances in Polymer-Based Vaginal Drug Delivery Systems.Pharmaceutics · 2021Review
- A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles.Heliyon · 2020Article
- Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells.Cell & bioscience · 2020Review
- Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir.Biomaterials · 2017Article
- Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized tumor tissue.Journal of nanobiotechnology · 2017Article
- A holistic approach to targeting disease with polymeric nanoparticles.Nature reviews. Drug discovery · 2015Review
- Nanoparticle-based drug delivery to the vagina: a review.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Controlled release for local delivery of drugs: barriers and models.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth.Advanced healthcare materials · 2014Article
- Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model.Drug delivery and translational research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Primary squamous cell carcinoma of the vagina is an uncommon disease that often exhibits few symptoms before reaching an advanced stage. Topical intravaginal therapies for resolving precancerous and cancerous vaginal lesions have the potential to be non-invasive and safer alternatives to existing treatment options. Two factors limit the testing of this approach: lack of a preclinical intravaginal tumor model and absence of safe and effective topical delivery systems. In this study, we present both an inducible genetic model of vaginal squamous cell carcinoma in mice and a novel topical delivery system. Tumors were generated via activation of oncogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.